MXC valued at A$0.11 per share based on Edison Investment Research., page-3

This was the report from October last year - and talks about the Cannaglobal deal version 1. We have version 2 now but that takes nothing away from the fact MXC off-loaded a loss making arm of its operations to an organisation better placed to see the Derma division expand to a greater extent than MXC would be able to do - and get continued rewards through supplying raw materials.

Other than that, it shows MXC in good light and that the future could be very rosy.

Thanks for sharing this and reminding us of the potential of that deal in North America.